Clinical Trial Update: A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis® [Phase 4]

View source ↗

Summary

Phase IV randomized, investigator-masked trial evaluating whether Loteprednol etabonate 0.5% ophthalmic gel influences initiation of Restasis treatment for Dry …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• Lotemax Ophthalmic Gel 0.5% (Loteprednol etabonate)
• Restasis (Cyclosporine A)

Snippet

Sponsor: Edward Holland, MD | Conditions: Dry Eye Disease | Phase 4 | Status: WITHDRAWN